| Loss of myosin light chain kinase induces the cellular senescence associated secretory phenotype to promote breast epithelial cell migration. | Loss of myosin light chain kinase induces the cellular senescence associated secretory phenotype to promote breast epithelial cell migration.
Kim D, Cooper JA, Helfman DM., Free PMC Article | 11/7/2024 |
| The SNHG12/microRNA-15b-5p/MYLK axis regulates vascular smooth muscle cell phenotype to affect intracranial aneurysm formation. | The SNHG12/microRNA-15b-5p/MYLK axis regulates vascular smooth muscle cell phenotype to affect intracranial aneurysm formation.
Feng W, Liang H, Liu D, Ruan S. | 02/9/2024 |
| Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease. | Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease.
Zuo L, Kuo WT, Cao F, Chanez-Paredes SD, Zeve D, Mannam P, Jean-François L, Day A, Vallen Graham W, Sweat YY, Shashikanth N, Breault DT, Turner JR., Free PMC Article | 04/7/2023 |
| The m(6)A methyltransferase METTL3 promotes trophoblast cell invasion by regulating MYLK expression. | The m(6)A methyltransferase METTL3 promotes trophoblast cell invasion by regulating MYLK expression.
Zhao J, Ding H, Ding J, Shi X, He Y, Zhu H, Yuan H, Zhang T, Zhang J. | 11/19/2022 |
| SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. | SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK.
Shi X, Yu X, Wang J, Bian S, Li Q, Fu F, Zou X, Zhang L, Bast RC Jr, Lu Z, Guo L, Chen Y, Zhou J., Free PMC Article | 07/9/2022 |
| CircMYLK promotes the growth, migration, invasion, and survival of bladder cancer cells by upregulating CCND3 level via competitively binding to miR-34a. | CircMYLK promotes the growth, migration, invasion, and survival of bladder cancer cells by upregulating CCND3 level via competitively binding to miR-34a.
Ye W, Chen L, Feng C, Liang T. | 04/2/2022 |
| Procyanidin A1 and its digestive products prevent acrylamide-induced intestinal barrier dysfunction via the MAPK-mediated MLCK pathway. | Procyanidin A(1) and its digestive products prevent acrylamide-induced intestinal barrier dysfunction via the MAPK-mediated MLCK pathway.
Yan F, Chen W, Zhao L, Lu Q, Wang C, Liu R. | 02/12/2022 |
| Myosin light chain kinase-driven myosin II turnover regulates actin cortex contractility during mitosis. | Myosin light chain kinase-driven myosin II turnover regulates actin cortex contractility during mitosis.
Taneja N, Baillargeon SM, Burnette DT., Free PMC Article | 02/12/2022 |
| CHD1L prevents lipopolysaccharide-induced hepatocellular carcinomar cell death by activating hnRNP A2/B1-nmMYLK axis. | CHD1L prevents lipopolysaccharide-induced hepatocellular carcinomar cell death by activating hnRNP A2/B1-nmMYLK axis.
Wang G, Zhang X, Cheng W, Mo Y, Chen J, Cao Z, Chen X, Cui H, Liu S, Huang L, Liu M, Ma L, Ma NF., Free PMC Article | 02/5/2022 |
| A novel tumor suppressor role of myosin light chain kinase splice variants through downregulation of the TEAD4/CD44 axis. | A novel tumor suppressor role of myosin light chain kinase splice variants through downregulation of the TEAD4/CD44 axis.
Huang YJ, Lee TC, Pai YC, Lin BR, Turner JR, Yu LC., Free PMC Article | 11/27/2021 |
| Silencing of long noncoding RNA MYLK-AS1 suppresses nephroblastoma via down-regulation of CCNE1 through transcription factor TCF7L2. | Silencing of long noncoding RNA MYLK-AS1 suppresses nephroblastoma via down-regulation of CCNE1 through transcription factor TCF7L2.
Zhu S, Zhang J, Gao X, Tang X, Cui Y, Li D, Jia W. | 10/23/2021 |
| MYLK and PTGS1 Genetic Variations Associated with Osteoporosis and Benign Breast Tumors in Korean Women. | MYLK and PTGS1 Genetic Variations Associated with Osteoporosis and Benign Breast Tumors in Korean Women.
Cho HW, Jin HS, Eom YB., Free PMC Article | 08/7/2021 |
| CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652. | CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652.
Zhao Y, Hu Y, Shen Q, Chen Q, Zhu XJ, Jiang SS, Zhang Q. | 04/3/2021 |
| Silencing of long noncoding RNA SRRM2-AS exerts suppressive effects on angiogenesis in nasopharyngeal carcinoma via activating MYLK-mediated cGMP-PKG signaling pathway. | Silencing of long noncoding RNA SRRM2-AS exerts suppressive effects on angiogenesis in nasopharyngeal carcinoma via activating MYLK-mediated cGMP-PKG signaling pathway.
Chen S, Lv L, Zhan Z, Wang X, You Z, Luo X, You H. | 03/13/2021 |
| Cardiac myosin regulatory light chain kinase modulates cardiac contractility by phosphorylating both myosin regulatory light chain and troponin I. | Cardiac myosin regulatory light chain kinase modulates cardiac contractility by phosphorylating both myosin regulatory light chain and troponin I.
Sevrieva IR, Brandmeier B, Ponnam S, Gautel M, Irving M, Campbell KS, Sun YB, Kampourakis T., Free PMC Article | 01/2/2021 |
| that AR-v12 is highly expressed in gastric cancer tissues and promotes migration and invasion through directly regulating MYLK | Androgen receptor variant 12 promotes migration and invasion by regulating MYLK in gastric cancer.
Xia N, Cui J, Zhu M, Xing R, Lu Y. | 04/11/2020 |
| nmMLCK is a potential molecular target to counteract early stages of atherosclerosis, such as endothelial dysfunction, inflammation through its capacity to increase transendothelial migration of monocytes and, most importantly, through the reorganization of VAMP-dependent vesicles associated with the release of IL-6 in modeled obstructive sleep apnea. | Non-muscular myosin light chain kinase triggers intermittent hypoxia-induced interleukin-6 release, endothelial dysfunction and permeability.
Recoquillon S, Gómez-Guzmán M, Rodier M, Koffi C, Nitiéma M, Gagnadoux F, Martínez MC, Andriantsitohaina R., Free PMC Article | 08/10/2019 |
| Report direct role for hnRNPA1 in MYLK alternative splicing in lung endothelial cells. | The Splicing Factor hnRNPA1 Regulates Alternate Splicing of the MYLK Gene.
Mascarenhas JB, Tchourbanov AY, Danilov SM, Zhou T, Wang T, Garcia JGN., Free PMC Article | 07/20/2019 |
| a unique domain within the MLCK splice variant MLCK1 directs perijunctional actomyosin ring (PAMR) recruitment. | Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis.
Graham WV, He W, Marchiando AM, Zha J, Singh G, Li HS, Biswas A, Ong MLDM, Jiang ZH, Choi W, Zuccola H, Wang Y, Griffith J, Wu J, Rosenberg HJ, Wang Y, Snapper SB, Ostrov D, Meredith SC, Miller LW, Turner JR., Free PMC Article | 05/11/2019 |
| We identified 2 novel disease-causing MYLK mutations using TAAD gene panel sequencing, 3explaining the cardiovascular phenotype in 0.6% of the cases (n = 358). Both heterozygous point mutations result in a pre-mature termination codon, probably leading tononsense-mediated mRNA decay and, hence, haploinsufficiency | Two novel MYLK nonsense mutations causing thoracic aortic aneurysms/dissections in patients without apparent family history.
Luyckx I, Proost D, Hendriks JMH, Saenen J, Van Craenenbroeck EM, Vermeulen T, Peeters N, Wuyts W, Rodrigus I, Verstraeten A, Van Laer L, Loeys BL. | 04/27/2019 |
| These data further define the aortic phenotype associated with MYLK pathogenic variants. Given minimal aortic enlargement before dissection, an alternative approach to guide the timing of aortic repair is proposed based on the probability of a dissection at a given age | MYLK pathogenic variants aortic disease presentation, pregnancy risk, and characterization of pathogenic missense variants.
Wallace SE, Regalado ES, Gong L, Janda AL, Guo DC, Russo CF, Kulmacz RJ, Hanna N, Jondeau G, Boileau C, Arnaud P, Lee K, Leal SM, Hannuksela M, Carlberg B, Johnston T, Antolik C, Hostetler EM, Colombo R, Milewicz DM., Free PMC Article | 03/16/2019 |
| This study found that MYLK gene Ala1491Ser mutation affect the kinase activity and clinically, it presents with vascular aneurysms and dissection. | Fatal thoracic aortic aneurysm and dissection in a large family with a novel MYLK gene mutation: delineation of the clinical phenotype.
Shalata A, Mahroom M, Milewicz DM, Limin G, Kassum F, Badarna K, Tarabeih N, Assy N, Fell R, Cohen H, Nashashibi M, Livoff A, Azab M, Habib G, Geiger D, Weissbrod O, Nseir W., Free PMC Article | 03/16/2019 |
| miR155 directly suppressed the expression of MYLK without affecting the RhoA pathway. | MicroRNA‑155 targets myosin light chain kinase to inhibit the migration of human bone marrow‑derived mesenchymal stem cells.
Wang X, Ye X, Ji J, Wang J, Xu B, Zhang Q, Ming J, Liu X. | 11/3/2018 |
| the MAPKspecific inhibitor SB203580 attenuated the inhibitory effects of 4HPR on the migration of HepG2 cells. Moreover, we also observed that 4HPR inhibited the activation and expression of myosin light chain kinase (MLCK) in HepG2 cells. | Fenretinide inhibits the proliferation and migration of human liver cancer HepG2 cells by downregulating the activation of myosin light chain kinase through the p38‑MAPK signaling pathway.
Zhang L, Huang D, Shao D, Liu H, Zhou Q, Gui S, Wei W, Wang Y. | 09/29/2018 |
| Recombinant human MLCK was concentration- and time-dependently degraded by recombinant human MMP9 in vitro, and this process was prevented by the MMP9 inhibitor. | Angiotensin II Facilitates Matrix Metalloproteinase-9-Mediated Myosin Light Chain Kinase Degradation in Pressure Overload-Induced Cardiac Hypertrophy.
Wang S, Cheng M, Hu Z, Hu S, Zou Q, Lai X, Liu B, Jiang H, Huang C, Wu G. | 03/17/2018 |